Immunoglobulins in chronic inflammatory demyelinating polyneuropathy.

  • Comi G
  • Quattrini A
  • Fazio R
 et al. 
  • 3

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

This article reviews the efficacy and tolerability of intravenous immunoglobulins (IVIg) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), including those forms associated with monoclonal gammopathy (paraproteinemic demyelinating neuropathy, PDN). Class I trials demonstrated that IVIg are effective in CIDP. About two-thirds of patients respond to initial treatment; however, most of them require repeated drug doses to maintain improvement. For PDN there are some evidences that IVIg are efficacious; however, it seems that less than 50% of the patients respond to this treatment and the persistence of the response over time has not been thoroughly investigated. The safety profile of immunoglobulins is generally good; however, the possibility of the occurrence of serious adverse effects should always be considered before starting treatment.

Author-supplied keywords

  • Chronic Disease
  • Demyelinating Diseases
  • Demyelinating Diseases: drug therapy
  • Humans
  • Immunoglobulins, Intravenous
  • Immunoglobulins, Intravenous: therapeutic use
  • Inflammation
  • Inflammation: drug therapy
  • Paraproteinemias
  • Paraproteinemias: drug therapy
  • Polyneuropathies
  • Polyneuropathies: drug therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • G Comi

  • a Quattrini

  • R Fazio

  • L Roveri

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free